141 results on '"Malczewska, Anna"'
Search Results
2. Circulating biomarkers of gastroenteropancreatic and lung neuroendocrine neoplasms: “The times they are a changin”
3. Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood.
4. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors
5. Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection
6. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
7. Therapy for Metastatic Disease: Pancreas
8. Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors: A Potential Tool for Diagnosis and Assessment of Effectiveness of Surgical Resection
9. Development and validation of a multigenomic liquid biopsy (PROSTest) for prostate cancer detection.
10. How Does Super Resolution for Satellite Imagery Affect Different Types of Land Cover? Sentinel-2 Case.
11. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression†
12. Gastroduodenal neuroendocrine neoplasms including gastrinoma — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma — uaktualnione zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]
13. Colorectal neuroendocrine neoplasms — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita grubego — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)]
14. Neuroendocrine neoplasms of the small intestine and the appendix — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]
15. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zaleceń ogólnych dotyczących postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]
16. Pancreatic neuroendocrine neoplasms — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne trzustki — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)]
17. Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy
18. Aktualizacja zaleceń ogólnych dotyczących postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowanych przez Polską Sieć Guzów Neuroendokrynnych).
19. NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis
20. Post-operative NETest scores detect residual NET disease and accurately predicts tumor recurrence in R0
21. Blood-Based Neuroendocrine Tumor mRNA Signature Identifies Residual Disease and at Day 30 after Operation Predicts Tumor Recurrence with 98% Specificity
22. Multigene liquid biopsy (NETest) is diagnostic of pancreatic and small bowel neuroendocrine tumours and correlates with imaging
23. Abstract 3389: A multi-gene prostate cancer liquid biopsy with > 92% accuracy in diagnosis and assessment of disease status
24. Abstract 1999: Diagnostic utility of the NETest in neuroendocrine transformed prostate cancer
25. Inefficacy of chromogranin a assays as neuroendocrine tumor diagnostic tools compared to the NETest.
26. A blood-based multi-mRNA liquid biopsy with >90% accuracy for diagnosis and assessment of prostate cancers.
27. A genomic blood test (NETest) identifies neuroendocrine transformation of prostate cancer.
28. The utility of blood-based molecular tools-the NETest-to monitor and evaluate the efficacy of PRRT in neuroendocrine tumors.
29. A multi-gene colorectal cancer liquid biopsy with >90% accuracy in diagnosis and assessment of disease status.
30. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience
31. Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy
32. ENETS single center of excellence experience with the NETest: A real-world assessment of 565 patients.
33. A 13-gene colorectal cancer liquid biopsy with greater than 90 percent accuracy in diagnosis and assessment of disease status.
34. PRRT neuroendocrine tumor response assessment using blood transcript analysis: The NETest.
35. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
36. Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors A Potential Tool for Diagnosis and Assessment of Effectiveness of Surgical Resection.
37. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
38. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis
39. Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis
40. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms
41. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging
42. Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus
43. NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease
44. Validation of the NETest liquid biopsy as a diagnostic for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
45. NETest liquid biopsy is diagnostic of lung neuroendocrine tumors and identifies progressive disease
46. Automated finger prick genomic diagnosis of neuroendocrine tumors
47. Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease
48. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
49. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
50. The NETest
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.